This $8 Stock Could Zoom 50%-100% to $12-$16 by July 31st – Act NOW!

 

Dear Investor –

 

We wanted to tell you about an incredible opportunity that is about to play out over the next few weeks on a stock that could make a very explosive move. We have been covering the company for a few years and we have actively been trading the stock and options heavily in 2018.

IMG_1864.png

The company develops a variety of prostate cancer treatments, highlighted by one candidate, currently in Phase IIb trial. The stock made a strong move in February from the $6 level to clear $8 and where we locked in our 46% winner using call options.

 

In late March, the company received notification from the FDA that it would be extending its review of the New Drug Application, or NDA, for the drug by three months to July 30th. The extension was the result of the submission of additional chemistry, manufacturing, and controls information by the company, which required additional time for the FDA to review. The standard 3-month extension is not related to the efficacy or safety data of the drug.

 

We reentered the trade again in early May when shares were just below $7 as momentum returned. We made another 70% when the stock made a run just past $9.

 

We are now back in the trade and the options we are recommending could easily double on good news. The stock closed Friday at $8.26 and the options were are suggesting are currently at 65 cents. If shares clear $12 the stock will make you roughly 50%. The options would be worth at least $2 on the move for a 200% return.

 

The drug’s injection cleared the primary endpoints in a Phase 2b trial and the important thing to remember.

 

The trial, which was performed under the Special Protocol Assessment (SPA) assessed the efficacy and safety of the therapy in patients suffering from two types of rare, devastating life-threatening, neuroendocrine tumors, including malignant and/or recurrent pheochromocytoma or paraganglioma.

 

A neuroendocrine tumor affects the hormone-producing cells of the body’s neuroendocrine system that comprises of cells which are a combination of hormone-producing endocrine cells and nerve cells. These cells control the flow of air, blood and food through the different body parts. There are no approved therapies available in the U.S. market for the two diseases.

 

During the trial, 17 of the 68 patients (25%) experienced a 50% or greater reduction of all antihypertensive medication for at least 6 months, thus meeting the trial’s primary endpoint. Antihypertensive medication is used for treating high blood pressure. The bulk of the trial patients taking the therapy also achieved partial tumor response.

 

The company also has 2 other potential money making drugs in development aside from the aforementioned one we have been covering with major news due out in a week, or less. The drug pipeline includes PSMA-targeted imaging agents for prostate cancer and imaging analysis technology. 

 

The company’s has already partnered with another well-known drug maker to produce the first commercial product for opioid-induced constipation. Given the partnership, and the company’s other 3 promising drugs, this stock is a longe-term hold. 

 

Our near-term price target is $12 but there are a few suit-and-ties on Wall Street that believe shares could trade towards $14-$16 on the news. We would love to see that but would be thrilled on a run past $12. 

 

Of course, there is risk to owning the stock and options if the news doesn’t favor the company, or if there is another snag. Owning the stock we be less risky as you can still own the stock for the long haul. The options we are recommending expire in mid-August and will give the trade plenty of time to play out. 

 

We want you in this trade ahead of next Monday’s major news anoouncement (or sooner) and we are offering a super deal to get you on board. Join now and save 50% by using the coupon code SAVE50. The 2-year deal gets you into all of our trades for just over $50/ month. However, we are also offering the SAVE50 coupon to the 3-month; 6-month; and 1-year subscriptions.

 

2 years – $2,497

SAVE50 – $1,248.50

https://www.momentumoptions.com/checkout/?level=14

 

1 year – $1,497

SAVE50 – $748.50

https://www.momentumoptions.com/checkout/?level=13

 

6 month – $997

SAVE50 – $498.50

https://www.momentumoptions.com/checkout/?level=12

 

3 month – $599

SAVE50 – $298.50

https://www.momentumoptions.com/checkout/?level=18

 

We recently closed a 342% winner using American Airlines AAL put options and another 50% winner this month using XLE call options. In fact, our track record is 18-4 since mid-March in what has been a very volatile market this year.

 

MomentumOptions.com continues to stay hot and we want you in our next batch of trades. If you haven’t heard of us, we have become the premier website in finding explosive option trades for gains of 100%, 200%, 400%, 600%, and even 1,000% jaw-dropping returns. Please feel free to check out our 10-year track record available on the website.

 

We have live Text Trade Alerts so please email me your number if you subscribe.

 

Thanks again for your great patronage!

 

MomentumOptions.com